Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis
J Invest Dermatol, 2022.
Douroudis K, Ramessur R, Barbosa IA, Baudry D, Duckworth M, Angit C, Capon F, Chung R, Curtis CJ, Di Meglio P, Goulding JMR, Griffiths CEM, Lee SH, Mahil SK, Parslew R, Reynolds NJ, Shipman AR, Warren RB, Yiu ZZN, Simpson MA, Barker JN, Dand N, Smith CH; BADBIR; BSTOP Study Groups.
Read publication: J Invest Dermatol
Related
Biosimilars for the Treatment of Psoriasis A Systematic Review of Clinical Trials and Observational ...
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study...
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for pa...
0 Comments